EcoDrugPlus

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSLCRG00005009978
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSLCRG00005022918
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSLCRG00005014987
Gene Symbol: CHRM2A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSLCRG00005017682
Gene Symbol: CHRM5A
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSLCRG00005019059
Gene Symbol: CHRM5B
3 Cross references
189 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSLCRG00005013513
Gene Symbol: F2R
3 Cross references
216 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSLCRG00005023653
Gene Symbol: F3A
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii, Like

Ensembl ID : ENSLCRG00005005330
Gene Symbol: F7L
1 Cross references
78 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSLCRG00005005260
Gene Symbol: F10
3 Cross references
240 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSLCRG00005013250
Gene Symbol: LOC104920427
2 Cross references
196 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSLCRG00005013260
Gene Symbol: LOC104920445
2 Cross references
196 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSLCRG00005013262
Gene Symbol: LOC113747205
2 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).